Botulinum neurotoxin (BoNT) type FA is the only known naturally occurring chimeric BoNT of domains of BoNT/A and BoNT/F. BoNT/FA consists of an F5-like light chain (LC), a unique heavy chain (HC) translocation domain, and a HC receptor binding domain similar to BoNT/A1. Previous analyses of purified BoNT/FA have indicated a 5e10-fold greater potency in cultured human or rat neurons as compared to BoNT/A1 and a 400e500-fold greater potency compared to BoNT/B1. However, in vivo potency in mice was about 5-fold lower than BoNT/A1 or/B1. In this report, species specificity was examined by cell-based assays using primary neurons from mice and examining VAMP1 and 2 cleavage. The data indicated similar potency of BoNT/FA in primary mouse spinal cord neurons as previously observed in primary rat and human induced pluripotent stem cell (hiPSC) derived neuronal cell models, and equal enzymatic cleavage of mouse VAMP1 and 2 isoforms. Since the duration of action of BoNTs is due to continuous enzymatic activity of the LC in the neuronal cytosol, BoNT/FA was expected to have a short duration of action due to its F-type LC. In this report the duration of action of BoNT/FA was compared to that of BoNT/ F1,/F5, and/B1 in both hiPSC derived neurons and in the in vivo mouse model. The data indicate a duration of action of BoNT/FA similar to BoNT/B1, while BoNT/F5 had a short duration of action similar to BoNT/F1.
Introduction
Botulinum neurotoxins (BoNTs) are extraordinarily potent protein toxins produced primarily by bacteria of the diverse species Clostridium botulinum. In addition to the diverse genetic background of the clostridia that produce BoNTs (Hill et al., 2007 (Hill et al., , 2015 Peck, 2009; Stringer et al., 2013) , the toxins themselves comprise a large family of over 200 isotypes that differ in their amino acid composition and structure to varying degrees (Hill and Smith, 2013; Hill et al., 2015; Montecucco and Rasotto, 2015) . All BoNTs consist of a light chain (LC) domain, which encodes a zinc-dependent endopeptidase that cleaves and inactivates essential proteins of the neuronal transmitter release machinery, and a heavy chain (HC), which facilitates neuronal cell binding and entry via its receptor binding domain (H C ) and translocation into the cell cytosol via its translocation domain (H N ) (Montal, 2010) . Historically and because of clinical significance, BoNTs have been categorized into seven immunologically distinct serotypes, named A-G (Gimenez and Gimenez, 1995) . In addition to immunological differences, the seven serotypes also have other distinct properties, including various durations of action of the LC, distinct neuronal cell receptors and affinities, and different enzymatic cleavage targets (Binz, 2013; Montecucco and Rasotto, 2015; Pellett, 2015; Rummel, 2013) . Duration of action of the BoNT LC activity is a major factor in severity of botulism, and mortality rate correlates with duration of action of the BoNT (Eleopra et al., 1998 (Eleopra et al., , 2006 Johnson and Montecucco, 2008; Pellett, 2015; Sloop et al., 1997) . The duration also impacts medical interventions including the need for and efficacy of respiratory support. Of the BoNTs affecting humans, BoNT/ A is considered to be the serotype with the longest duration of action, lasting from several months to over a year depending on the dose and subtype. This is followed by BoNT/B, which can also cause paralysis for several months, and BoNT/E and BoNT/F, which result in a shorter paralysis lasting from a few weeks to about a month (Blitzer, 2005; Dressler, 2016; Eleopra et al., 1998 Eleopra et al., , 2004 Johnson and Montecucco, 2008; Keller, 2006; Montecucco and Rasotto, 2015; Sloop et al., 1997) . In the USA, the mortality rate for botulism cases caused by BoNT/A is approximately 5% and intubation rate over 80%, whereas mortality for BoNT/B and E is 1e3% and intubation is required in about 30% of cases. Botulism caused by BoNT/F is rare and has a significantly shorter duration of action of a few days to about one month. While most foodborne botulism cases caused by type F are mild, some severe cases and deaths have been reported (Jackson et al., 2015; Johnson and Montecucco, 2008) .
Importantly, while some of our knowledge on biologic characteristics of BoNT serotypes is based on epidemiological and clinical data, specific knowledge such as detailed studies on duration of action is usually based on studies of the first identified subtype of each serotype. However, large scale sequencing efforts during the past~10 years have revealed that many genetic variants exist within the seven serotypes. Toxin variants are currently categorized as new subtypes of a serotype if they differ by more than 2.6% in their amino acid sequence. Sequences from over 40 subtypes have been published (Hill and Smith, 2013; Hill et al., 2015; Montecucco and Rasotto, 2015; Peck et al., 2017) . In addition, members of BoNT/ C and/D serotypes, which cause large scale avian and bovine botulism outbreaks (Friend and Milton, 1999; Souillard et al., 2014; Woudstra et al., 2016) , include several chimeric BoNTs denoted D/C or C/D and consisting of various LCH N -H C combinations (Hedeland et al., 2011; Nakamura et al., 2013; Takeda et al., 2005; Woudstra et al., 2016) . Intra-serotype chimeric toxins combining HC and LC domains of subtypes within one serotype have also been reported including BoNT/A2 and BoNT/F5 (Hill et al., 2007; Raphael et al., 2010) . No chimeric toxins had been reported combining two or more serotypes of BoNTs other than C and D until the report of a novel BoNT from a Clostridium strain (IBCA107060) isolated from an infant botulism case in California, USA Dover et al., 2014) . Culture supernatants from this strain, which also produces a second BoNT, BoNT/B2, was initially reported not to be neutralized by the CDC standard diagnostic antitoxins for BoNT serotypes A-G and the toxin was proposed as a new serotype 'H' Dover et al., 2014) . However, later studies using culture supernatants and purified BoNT/FA confirmed neutralization of this toxin by polyclonal research antibodies raised against BoNT/A1, although at about 20-fold lower efficiency than neutralization of BoNT/A1, and showed that the therapeutically used heptavalent hBAT fully protected mice against intoxication by BoNT/FA Pellett et al., 2016) . Recent structural and monoclonal antibody analyses of neutralization and binding further confirmed some similarities and some uniqueness of the H C domain of this toxin with BoNT/A1, while the H N and LC had relatively low sequence and surface identity or immunological similarity to BoNT/F1, and the name BoNT/HA was proposed (Fan et al., 2016; Yao et al., 2017) . The BoNT/FA LC and N-terminal portion of the H N domain is most similar to BoNT/F5. BoNT/F5 is unique amongst the serotype F subtypes in that it has a low degree of amino acid similarity to other BoNT/F subtypes (~70%), has been described as an intra-serotype hybrid consisting of an F2-like HC and unique LC (Raphael et al., 2010) , and has a unique VAMP cleavage site (Kalb et al., 2012) , which is shared only by BoNT/FA (Kalb et al., 2015) .
Despite high amino acid similarity of the LCs of BoNT/A subtypes, recent analyses have identified a subtype (BoNT/A3) with significantly shorter duration of action than other A subtypes (Pellett et al., 2015b; Whitemarsh et al., 2014) , indicating that duration of action of subtypes within one serotype may vary. In the present report, the duration of action of BoNT/FA was examined in cultured neurons and in vivo. The data indicate that even though the LC of the chimeric BoNT/FA is most similar to subtype BoNT/F5, the duration of action is significantly longer than that of BoNT/F1 and/F5 and more similar to that of BoNT/B1. This report also describes the first isolation and potency characterization of BoNT/F5. 
Materials and methods

Biosafety and biosecurity
Botulinum neurotoxins
Purification, trypsin activation, and characterization of BoNT/FA from strain CDC69016/B2tox À has previously been described . BoNT/B1 was purified from C. botulinum strain Okra B and trypsin activated as described (Prabakaran et al., 2001) , and endogenously activated BoNT/F1 was purified from C. botulinum strain Langeland F as previously described (Malizio et al., 2000) . The purified toxins were stored in phosphate buffered saline at pH 7.0 with 40% glycerol at À20 C until use. BoNT/F5 was purified from C. botulinum strain CDC 54075 using methods similar to those used for type E and A toxin purification (Prabakaran et al., 2001) . Briefly, strain CDC 54075 was grown for 48 h at 32 C and extracted as described (Prabakaran et al., 2001) . A ribonuclease A digest step was performed as described previously (Prabakaran et al., 2001) , followed by DEAE sephadex chromatography at pH 5.5. and 7.9 as previously described (Malizio et al., 2000) . This was followed by ion exchange chromatography using a source 15Q column (GE Healthcare Life Sciences). The BoNT/F5 was eluted using a NaCl gradient from 0 to 0.3M. BoNT/F5 was stored in phosphate buffered saline at pH 8.0 with 40% glycerol at À20 C until use. Trypsin treatment did not increase biologic activity of purified BoNT/F5 in the mouse bioassay, and therefore was not done on the toxin stocks used in this study. All toxins were about 95e98% pure as estimated by SDS-PAGE gel analysis and densitometry (Fig. 1) . Toxin concentration was determined by optical density at A 278 using an extinction coefficient of 1.63 for BoNT/FA,/ F1, and/F5, and 1.85 for BoNT/B1. Specific activity of all toxins was determined using a standard intraperitoneal mouse bioassay (MBA) as previously described (Hatheway, 1988; Schantz, 1978) , with the half-lethal dose of each toxin defined as 1 mouse LD50 Unit (U). Specific activity was 3.8 Â 10 7 mouse LD50 U/mg for BoNT/FA, 5 Â 10 8 LD50 U/mg for BoNT/B1, and 7.7 Â 10 7 LD50 U/mg for BoNT/ F1 and 3.2 Â 10 5 LD50 U/mg for BoNT/F5 (Table 1) .
Neuronal cell cultures
Cell based assays were performed essentially as previously described (Pellett et al., 2007; Whitemarsh et al., 2012) . Primary mouse spinal cord (MSC) cells were prepared from E12 ICR mouse pups and seeded into 96-well TPP plates that had been coated with 0.01% poly-L-ornithine and 8.3 mg/cm 2 matrigel at a density of 70,000 cells/well. The MSC cells were maintained in Neurobasal media (Neurobasal culture media supplemented with B27, glutamax, and penicillin/streptomycin, all from Life Technologies) with bi-weekly changes of the media. The cells were maintained for at least 19 days in culture before use in a toxin assay.
Human induced pluripotent stem cell (hiPSC) derived neurons (iCell Neurons) were purchased from Cellular Dynamics International (CDI, Madison, WI). The cells were seeded into 96-well TPP plates (Techno Plastic Products, Midwest Scientific, Valley Park, MO) that had been coated with 0.01% poly-L-ornithine and 8.3 mg/ cm 2 Matrigel (BD Biosciences, East Rutherford, NJ) at a density of about 35,000e40,000 cells per well and maintained in culture media (provided by the company) as per company instructions. Cells were maintained for at least 5 days post seeding before use in a toxin assay.
Cell-based toxin activity assay
Toxin activity was determined in MSC cells. Serial dilutions of purified BoNT/FA were prepared in the culture medium, and MSC cells were exposed to the serial toxin dilutions in 50 ml of Neurobasal media for 48 h at 37 C, 5% CO 2 in triplicate, respectively. After 48 h, the toxin was aspirated from the cells, and cell lysates were prepared in 75 ml of lithium dodecyl sulfate (LDS) sample buffer (Life Technologies) and heated to 95 C. The cell lysates were analyzed by Western blot for VAMP1 and VAMP2 cleavage as previously described (in relation to syntaxin) using monoclonal VAMP1 specific (Abcam) or VAMP2 and syntaxin1 specific (Synaptic Systems) antibodies (Pellett et al., 2007 (Pellett et al., , 2010 . Images were obtained using PhosphaGlo reagent (KPL, Gaithersburg, MD) and a Fotodyne/FOTO/Analyst FX imaging system (Harland, WI), and the VAMP1 and VAMP2 signals were analyzed in relation to the syntaxin signal (loading control) by densitometry using TotalLab Quant software (Fotodyne, Harland, WI) . EC50 values were estimated using GraphPad Prism 6 software and a nonlinear regression, variable slope, four parameters (EC50, Hill slope, top and bottom plateaus).
2.5. In vitro toxin activity assay using MSC cell lysates VAMP1 and VAMP2 cleavage by BoNT/FA, BoNT/F1, and BoNT/B1 was compared in vitro using cell lysates prepared from MSC cells. For preparation of cell lysates, MSC cells were prepared as described above but seeded into 6-well plates at a density of about 2 Â 10 6 cells/well. After at least 19 days in culture, cell lysates were prepared. The cells were washed in DPBS (Life Technologies), and 1.5 ml of MPER mammalian cell lysis buffer (Thermo Scientific) containing 5 mM NaCl was added to each well. The cells were scraped off the surface of the plate with a cell scraper, cell clumps dispersed by pipetting, and cell lysis was allowed to proceed for 10 min at room temperature. Cell lysates were centrifuged at 14,000Âg for 5 min to remove any insoluble cell debris, and used immediately in the in vitro assay. For the in vitro assay, serial dilutions of BoNT/FA,/F1, or/B1 were prepared in 20 ml of 4Â reaction buffer (150 mM Hepes, pH 7.0, 15 mM NaCl, 30 mM ZnCl 2 , 10 mM DTT). The toxin dilutions were incubated for 15 min prior to addition of cell lysates to allow for reduction of the toxins in the DTT containing buffer. To start the enzymatic reaction, 60 ml of cell lysate was added to each toxin dilution, and the mixtures were incubated at 37 C for 30 min. The reactions were stopped by addition of LDS sample buffer (Life technologies) to 1 Â and heating of the samples to 95 C. All toxin dilutions were tested in triplicate. The three BoNT serotypes were all tested in parallel using the same cell lysate, and a negative control not containing any toxin was included. In addition, triplicate samples of cell lysate in reaction buffer at 0 min were also analyzed to ensure no degradation of VAMP1 and 2 in the assay.
Cell-based duration of action assay
To determine BoNT/LC duration of action in hiPSC derived neurons, the neurons were exposed to serial dilutions of either BoNT/FA, BoNT/B1, BoNT/F1, or BoNT/F5 in culture media for 48 h. After 48 h, the toxin was removed and cells were washed two times with 300 ml of culture media. Cells were then returned to the incubator and half of the media was replaced every 3e4 days. Triplicate sets of the dilutions series of BoNT/B1 and FA were harvested at days 3, 15, and 25 post first addition of toxin. Triplicate sets of the dilution series of BoNT/F1 were harvested at days 3, 4, 7, and 8. Triplicate sets of the dilution series of BoNT/F5 were harvested at days 2 and 7. To harvest cells, media was removed and cells were lysed in 1Â LDS sample buffer. Cell lysates were heated to 95 C, and VAMP2 levels were determined in relation to syntaxin as previously described (Whitemarsh et al., 2012) . Images of the Western blots were obtained using PhosphaGlo reagent (KPL, Gaithersburg, MD) and a Fotodyne/FOTO/Analyst FX imaging system (Harland, WI). The VAMP2 signal in relation to the syntaxin signal (loading control) was analyzed by densitometry using TotalLab Quant software (Fotodyne, Harland, WI) . EC50 values were determined using GraphPad Prism 6 software and a nonlinear regression, variable slope, four parameters. EC50 values were plotted versus time in excel using an XY scatter plot, and fitted with an exponential trend line. The half-life for VAMP2 recovery was determined from the slope of the trend line using the formula t1/ 2 ¼ LN(2)/slope.
Mouse assays to determine onset and duration of action of BoNTs
In vivo duration of action was determined by DAS (digital abduction score) and Rotarod analysis as previously described (Pellett et al., 2015b) . Briefly, groups of 5 female ICR mice (Harlan) were injected into the right gastrocnemius muscle with the indicated sub-lethal amounts of BoNT/B1, BoNT/FA, BoNT/F1, or BoNT/ F5 in 10 ml of GelPhos buffer (30 mM sodium phosphate [pH 6.3] and 0.2% gelatin) using a 0.3 ml insulin syringe with 5 ml increment markings. The maximum sub-lethal amount by injection into the gastrocnemius was determined empirically for each toxin and was used as the highest amount. The injected dose of each toxin was confirmed by mouse bioassay (Hatheway, 1988; Schantz, 1978) using the same toxin dilution as was used for the intramuscular injection. The ability of the mice to remain running on a Rotarod (MED-Associates) using an accelerating cycle of 4e40 rpm over 5 min was recorded initially at 0 h, 5 h, 8 h, 12 h, 25 h, 31 h, 49 h post injection, and then daily thereafter until full recovery. The latency time on the rotarod was determined on a scale from 0 to 1, where 0 equates to a complete inability to remain on the rotarod and 1 equates to the maximum amount of time tested (300 s). Graphs showing the average and standard deviation of the 5 mice per group were prepared using an XY scatter plot in Microsoft Excel. The DAS score was determined prior to running on the Rotarod on the same groups of mice, and the averaged and standard deviation for each group at each time point was determined.
Immunocytochemistry
For immunocytochemistry, primary mouse spinal cord cells from E12 ICR mouse pups were seeded onto glass coverslips that had been coated with 0.01% poly-L-ornithine and 8.3 mg/cm 2 matrigel at a density of 175,000 cells/ml. The MSC cells were maintained for 19 days in Neurobasal media with bi-weekly changes of the media. The Neurobasal medium was removed and cells were washed in warm Dulbecco's Phosphate buffer saline (DPBS, Life Technologies). Cells were fixed in 4% paraformaldehyde for 15 min at ambient temperature, followed by 4 washes with DPBS, and incubation for 1 h at ambient temperature with blocking buffer (DPBS (Life Technologies) containing 10% w/v saponin, 0.1% Tween 20, 1% bovine serum albumin, and 22.52 mg/ml glycine, all from SIGMA). The following dilutions of primary antibodies were added in blocking buffer and incubated over-night at 4 C. To determine VAMP1 expression patterns: anti-VAMP1 (Abcam) at 1:250 dil., anti-MAP2 (Life Technologies) at 1:10,000 dil., and anti-GFAP (Life Technologies) at 1:100 dil., and to determine VAMP2 expression patterns: anti-VAMP2 (Synaptic Systems) at 1:1000 dil., anti-MAP2 (Life Technologies) at 1:10,000 dil., and anti-GFAP (Life Technologies) at 1:100 dil. The antibodies were removed and cells were washed 4 Â 15 min with DPBS. Secondary antibodies were added at a 1:500 dilution in blocking buffer as follows. For VAMP1 detection, Alexa Fluor 488 conjugates goat anti-rabbit IgG (H þ L), Alexa Fluor 546 conjugated goat anti-chicken IgG (H þ L), and Alexa Fluor 350 goat conjugated anti-rat IgG (H þ L) (all highly crossabsorbed and all from Life Technologies) were used, and for VAMP2 detection, Alexa Fluor 488 conjugates goat anti-mouse IgG (H þ L), Alexa Fluor 546 conjugated goat anti-chicken IgG (H þ L), and Alexa Fluor 350 goat conjugated anti-rat IgG (H þ L) (all highly cross-absorbed and all from Life Technologies) were used. Cells were incubated with secondary antibodies for 1 h at ambient temperature, antibodies were removed, and cells washed 4 Â 15 min in DPBS. For negative controls, cells were similarly treated but only exposed to the secondary antibodies. The coverslips were mounted cell-side down on microscope slides using CitiFlour AF3 mounting reagent (Electron Microscopy Sciences), and observed using a Zeiss AxioSkop 2 plus, and photographed with a Jenoptik ProgRes MF camera and analyzed using ProgRes Capture Pro v2.8.8.
Results
BoNT/FA potently cleaves VAMP1 and VAMP2 in primary mouse spinal cord cells
Previous analyses have indicated that BoNT/FA was about 10-fold more potent in human induced pluripotent stem cell (hiPSC) derived neurons than BoNT/A1, yet it was about 4e5-fold less potent in in vivo assays in mice . In order to determine whether this apparent difference is due to species specificity or to other factors, potency of BoNT/FA in primary mouse spinal cord (MSC) cells was determined. Exposure of the cells to serial dilutions of BoNT/FA for 48 h resulted in efficient VAMP1 and VAMP2 cleavage with an EC50 of about 0.07 U/well (243 fM) for VAMP2 and 0.008 U/well (28 fM) for VAMP1 (Fig. 2) . This is similar to the potency previously observed in hiPSC derived neurons and in rat spinal cord neurons . As is usually observed in BoNT assays with primary spinal cord cell preparations, the VAMP2 signal was only reduced by 50e60% (Eleopra et al., 2013; Pellett et al., 2007 Pellett et al., , 2015a , whereas VAMP1 was fully cleaved (Fig. 2A) . Primary spinal cord cultures contain a mixture of neuronal and glial cells, and it has previously been shown that VAMP2 is expressed in both glial and neuronal cells whereas VAMP1 is not expressed in glial cells. Immunocytochemistry analysis of the MSC cultures used in these experiments confirmed absence of VAMP1 in glial cells, whereas VAMP2 was detected in both glial and neuronal cells (Fig. 2B) .
In order to examine whether the partial VAMP2 cleavage in MSC cells was due to differential enzymatic cleavage of VAMP1 and VAMP2 by BoNT/FA, or to differential cell entry into neuronal and glial cells, an in vitro enzymatic cleavage assay was conducted using cell lysates prepared from primary mouse spinal cord cells. Incubation of cell lysates with serial dilutions of BoNT/FA and BoNT/F1 for 0.5 h resulted in efficient and equal cleavage of VAMP1 and VAMP2, and incubation with BoNT/B1 resulted in slightly more efficient VAMP1 cleavage (Fig. 2C) . Interestingly, the EC50 values of BoNT/FA in this in vitro endopeptidase assay were about 10-fold lower than those of BoNT/F1 or/B1 (Fig. 2C) , indicating that the BoNT/FA LC has high enzymatic activity. BoNT/F5 could not be investigated in the in vitro enzymatic cleavage assay because the low expression levels of this toxin did not allow for purification of sufficient amounts for this assay.
BoNT/FA has a similar half-life as BoNT/B1 in hiPSC derived neurons
In order to further explore potential reasons for the discrepancy in BoNT/FA potency in cultured neurons versus in vivo potency, the duration of action of BoNT/FA compared to that of BoNT/F1, BoNT/F5, and BoNT/B1 was compared in hiPSC derived neurons. It is well known that BoNT/B1 has a relatively long duration of action in humans, enabling its use as a long-lasting pharmaceutical, whereas BoNT/F1 has a much shorter duration of action with recovery within a few days to weeks (Eleopra et al., 2004) . The duration of action of BoNT/F5 was unknown, as this toxin has not previously been purified and analyzed. Since the LC of BoNT/FA is most similar in amino acid sequence to that of BoNT/F5, purified BoNT/F5 was produced to enable comparative analyses (Fig. 1) . The specific activity of the purified BoNT/F5 was determined in three independently produced batches using the mouse bioassay, and reproducibly was found to be about 3 Â 10 5 mLD50 U/mg, which is about 500-fold lower than the specific activity of most other BoNTs. The half-life of the BoNT/FA,/B1,/F5, or/F1 light chains (LC) in hiPSC derived neurons were estimated by exposing the neurons to serial dilutions of each BoNT for 3 days, followed by removal of the toxin and further incubation of the cells. Cells from each dilution series were harvested at the indicated time points post first toxin addition, and EC50 values for VAMP2 cleavage were determined by analyzing cell lysates for VAMP2 levels relative to syntaxin by Western blot and densitometry (Fig. 3) . The approximate half-life for VAMP2 recovery was determined from the slope of a fitted regression line through the EC50 values versus time (Fig. 3) . These data showed a similar duration of action of the BoNT/FA and BoNT/B1 LCs inside cultured human neurons, with half-lives of about 5e8 days. BoNT/F1 LC, on the other hand, had an estimated half-life of 0.8 days. Due to the low specific activity of BoNT/F5, only partial data could be obtained for this toxin. However, the data clearly and reproducibly showed faster recovery similar to BoNT/F1, with an estimated half-life of about 2 days (Fig. 3) . In vitro analysis of VAMP1 and 2 cleavage in MSC cell lysates. MSC cells lysates were prepared and incubated with the indicated concentrations of BoNT/FA,/F1, or/B1 for 30 min at 37 C after reduction of the toxins with DTT. VAMP1 and 2 cleavage was determined by Western blot and densitometry, and the average and standard deviation of triplicate samples is shown, respectively. Prism 6 was used to generate a non-linear regression fit and estimate the EC50 values for VAMP1 and 2 cleavage, respectively. 95% confidence intervals for the EC50 estimates were: BoNT/ FA: 0.15e0.21 (VAMP1), 0.16e0.3 (VAMP2), BoNT/F1: 1.2e1.9 (VAMP1), 2.07e2.1 (VAMP2), BoNT/B1: 1.2e2.7 (VAMP1), 9.5e28.2 (VAMP2).
BoNT/FA has a similar duration of action as BoNT/B1 in mice
Duration of action was further examined using the in vivo mouse model. Mice were injected with sublethal doses of BoNT/FA, BoNT/ B1, BoNT/F5, or BoNT/F1 into the gastrocnemius muscle of the right hindlimb. The mice were evaluated for local paralysis using the digital abduction score (DAS) assay and for motor-neuron deficiency using an accelerating Rotarod. Mice injected with BoNT/FA had a slightly slower increase in the DAS score as compared to mice injected with BoNT/B1,/F5, or/F1, with an about 4 h delay (Fig. 4) . However, the maximum DAS score was maintained for a similar duration in mice injected with BoNT/FA and BoNT/B1, followed by a similar slow decline over the next week. Mice injected with BoNT/ F1 or BoNT/F5 on the other hand, recovered from the maximal DAS score much quicker and were fully recovered by day 4 (Fig. 4) . Interestingly, analysis of motor-neuron deficiency of the whole animal as measured by Rotarod showed a delay in onset of motorneuron deficiency in mice injected with BoNT/FA as compared to mice injected with BoNT/B1. Mice injected with BoNT/FA were able to remain on the Rotarod for the entire 5 min time period until day 3 with a maximum decrease reached at day 4e6, whereas mice injected with the same doses of BoNT/B1 were unable to run the entire 5 min starting at day 2 and reached a maximum decrease in running time at day 3. In addition, there was a clear difference in the maximum decrease in running time between mice injected with BoNT/FA and BoNT/B1, with the mice injected with 0.75 U of BoNT/B1 falling off the Rotarod after 15 s, whereas the mice injected with 0.75 or 1 U of BoNT/FA remained on the Rotarod for over 1.5 min (data for the 1 U not shown). While mice injected with 0.75 U of BoNT/B1 recovered fully within 10 days in the Rotarod assay, mice injected with 0.75 U of BoNT/FA required 13 days for full recovery. Considering the later onset of motor-neuron deficiency in mice injected with BoNT/FA, the time period required for full recovery was similar in mice injected with either toxin, but overall motor-neuron deficiency severity was milder than in mice injected with BoNT/B1. Mice injected with the same doses of BoNT/F1 or BoNT/F5 were able to remain on the Rotarod the entire 5 min time period throughout the study, most likely due to the fast recovery preceding the onset of detectable motor-neuron deficiency of the whole animal at the tested doses. In the case of BoNT/F5, even mice injected with 3 U, which by intraperitoneal injection would be expected to be lethal, only had a very minor decrease in time on the Rotarod (Fig. 4) .
Discussion
Botulinum neurotoxins comprise a large family of protein toxins, which are primarily categorized by their immunological properties into seven serotypes, A-G (Gimenez and Gimenez, 1995; Johnson and Montecucco, 2008) . Within most serotypes, several genetic variants have been identified and, with a few exceptions, are categorized as subtypes if they differ by more than 2.6% in their amino acid sequence (Hill and Smith, 2013; Hill et al., 2015; Montecucco and Rasotto, 2015; Peck et al., 2017) .
While biological and functional characteristics of most of the BoNT subtypes within a serotype have not yet been determined, the first identified subtype (designated by number 1 following the capital letter of the serotype) of each of the 7 described serotypes have been explored and differ from each other in their biologic properties in addition to their immunologic distinction, which affects their respective pathology (Johnson and Montecucco, 2008; Pellett, 2015) . These differences include distinct SNARE targets and cleavage sites, distinct receptor binding and cell entry properties, species specificity, and distinct duration of action. Accordingly, BoNT/A, with its great potency in humans and the longest duration of action of the seven serotypes, causes the most severe human botulism and is also the most commonly used BoNT-based therapeutic. BoNT/F, on the other hand, causes few adult human botulism cases, which are characterized by fast onset and fast recovery ( , and/F5 LCs in hiPSC derived neurons. The hiPSC derived neurons were exposed to serial dilutions of each toxin for 48 h, and all extracellular toxin was removed. Cells continued to be incubated at 37 C in fresh culture media. At the indicated time points, triplicate sets of cells exposed to the dilution series were harvested and analyzed for VAMP2 cleavage by Western blot. The top panel shows graphs depicting the average and standard deviations of triplicate samples at each time point, and non-linear regression fits to determine the EC50 values (Prism 6 software), respectively. The bottom panel shows XY scatter blots of the EC50 values versus time and an exponential trendline fitted through the EC50 values. The half-life for recovery was determined from the slope of the trendline using the formula t1/2 ¼ LN(2)/slope. Note: The EC50 value at day 7 for BoNT/F5 was estimated by curve projection, since the low activity of BoNT/F5 combined with low recoveries from purifications limited the doses that could be used in this assay. and therapeutic use in humans resulted in benefits for only a short time period (Greene and Fahn, 1993) .
While the unique SNARE target and cleavage site seems to be shared among the subtypes within one serotype, one notable exception is BoNT/F5, which not only is the most divergent in amino acid sequence of all BoNT/F subtypes, it also has a unique SNARE cleavage site (Kalb et al., 2012) . Interestingly, BoNT/FA (H) has a LC that is most similar in amino acid sequence to BoNT/F5 (Dover et al., 2014) , and it has been shown to cleave VAMP at the same cleavage site (Kalb et al., 2015) . This raises the question whether the LCs of BoNT/F5 and of BoNT/FA belong to a new and as yet not identified serotype ('H'). This is further supported by the chimeric structure of both BoNT/FA and BoNT/F5 (Dover et al., 2009; Raphael et al., 2010; Yao et al., 2017) . A protein blast using the amino acid sequence of the BoNT/F5 HC revealed an 89% identity to BoNT/F2, with the majority of the differences located in the N-terminal region of the HC, which comprises the belt-loop structure that wraps around the LC. The LC region, on the other hand, had greatest similarity to the LC of BoNT/FA (80% identical), whereas similarity to other BoNT/F LCs was as low or lower as the similarity to tetanus toxin (48% identity with BoNT/F1 and 46% identity with TeNT). Currently serotypes of BoNTs are distinguished based on immunological differences determined in a mouse neutralization study, which are to a large extent determined by the 100 kDa HC region of the toxins. No serologically distinct HC domain (putative BoNT/H HC) linked to a homologue of the unique LCs of BoNT/FA or F5 has been identified, complicating nomenclature of the chimeric BoNT/FA and/F5 toxins.
BoNT/F5 had not previously been purified, in part because little toxin activity was detected in culture supernatants from strains expressing BoNT/F5, indicating low expression levels. However, since the BoNT/F5 and/FA LCs are distinct from all other F subtypes in their VAMP cleavage site and amino acid homology, a comparative study on BoNT/FA LC characteristics required inclusion of BoNT/F5. Determination of specific activity of BoNT/F5 in mice indicated an unusually low activity of~3 Â 10 5 mLD50/mg, which is at least 500-fold lower than other BoNTs. So far only one other BoNT variant has been found to have a similarly low specific activity, BoNT/A4 (Bradshaw et al., 2014) . The reasons for the low activity of BoNT/F5 are currently unknown and may include a defect in receptor binding or cell entry, low enzymatic activity, or low stability of the toxin. BoNT/FA (H) has previously been shown to be about 10-fold more potent in cultured human and primary rat neurons than Fig. 4 . In vivo duration of action of BoNT/FA, B1, F1, and F5. Mice were injected with the indicated amounts of toxin into the right gastrocnemius muscle, and observed until fully recovered. Local paralysis was measured by observing toe-spread using the DAS score on a scale from 1 to 5 (right panels), and overall motorneuron deficiency was measured by Rotarod analysis using an accelerating rod (4e40 rpm over 5 min) (left panel). Five mice were used per group, and average and standard deviation are shown for each time point and toxin concentration. The graphs showing the data are xy scatter blots created in Excel. The maximum sub-lethal amount by injection into the gastrocnemius was determined empirically for each toxin and was used as the highest amount. Mice injected with BoNT/F1 and/F5 showed minimal motor-neuron deficiency as measured by Rotarod (flat lines).
BoNT/A1, whereas activity in mice was reduced about 4e5 fold and mice had a significantly slower progression of symptoms . In order to determine whether potential species specificity might account for this apparent discrepancy, VAMP1 and VAMP2 cleavage in cultured spinal cord neurons of the same species of mouse used for the in vivo studies was analyzed. The data indicated that BoNT/FA entered the cultured primary mouse neurons as efficiently as human cultured neurons and cleaved both VAMP1 and 2 efficiently (Fig. 2) , excluding species specific differences in neuronal cell entry and activity as an explanation for this observation.
Other factors that could account for the difference in potency in cultured neurons and in mice include onset and duration of action, or in vivo distribution of the toxin. Comparative studies of the duration of action of BoNT/FA,/B1,/F5 or/F1 in hiPSC derived neurons and in mice after local intramuscular injection indicated a duration of action of BoNT/FA similar to that of BoNT/B1, whereas the duration of action of BoNT/F1 and/F5 was very short (Figs. 3 and  4) . Since the LC of BoNT/FA is most similar to BoNT/F5, and the duration of action of BoNT/F5 is very short and similar to that of BoNT/F1 (Figs. 3 and 4) , the long duration of action of BoNT/FA was unexpected and underscores the importance of functional characterization of BoNT subtypes within one serotype. Previous studies comparing the duration of action of BoNT/A subtypes 1e5 revealed that BoNT/A3 has a significantly shorter duration of action than the other BoNT/A subtypes (Pellett et al., 2015b; Whitemarsh et al., 2014) . The findings presented here are the second study demonstrating variation in the onset and duration of action of subtypes within one serotype, which is a key characteristic of BoNTs with regards to pathology and clinical relevance. This raises the question of how many BoNT subtypes vary in their duration of action from the corresponding characterized subtypes within each serotype, and whether clinical identification of a serotype should automatically lead to an expectation on duration of action. In addition, these findings indicate that additional subtypes with unique pharmacologically advantageous properties within any serotype may be identified in the future.
The significantly delayed onset and milder extent of motorneuron deficiency caused by BoNT/FA as compared to BoNT/B1 is in accord with previous studies Pellett et al., 2016) showing delayed death in mice (Fig. 4) . However, the slight delay in local paralysis as measured by DAS score (Fig. 4) was surprising considering the high potency of this toxin in cultured neurons, which indicates efficient neuronal uptake and substrate cleavage. In fact, in previous studies a greater potency in cultured neurons by BoNT/A2 compared to BoNT/A1 seemed to correlate with faster onset of local paralysis (Pellett et al., 2015b; Pier et al., 2011; Whitemarsh et al., 2013) . The lack of observations of a faster onset of local symptoms by BoNT/FA could be due to biologic properties of this toxin or the testing parameters used in the DAS score assay.
Taken together the data presented in this study rule out species specificity and differential onset and duration of action of BoNT/FA as potential explanations for the discrepancy in activity in cultured neurons and in mice in vivo. This suggests that the discrepancy is likely due to unique in vivo distribution of BoNT/FA. Possible explanations are differential neuronal selectivity, intracellular trafficking of the toxin after endocytic uptake, or stability of the toxin in blood and tissue. Interestingly, a recent structural study of the BoNT/FA H C domain showed unique binding to gangliosides and the SV2 receptor (Yao et al., 2017) , suggestive of unique neuronal cell entry. Future research is required to address these aspects of BoNT/ FA pharmacological properties and to gain a better understanding of the molecular properties of the large family of BoNTs in general.
In summary, the presented data show that the mosaic BoNT/FA toxin is very potent in cultured human, rat, and mouse neurons and efficiently cleaves VAMP1 and 2 isoforms. In addition, the in vivo studies indicate that local intramuscular injection of BoNT/FA in mice results in local paralysis similar to that caused by equal doses of BoNT/B1, whereas there is a significant delay and reduction in general motor-neuron deficiency. These data suggest that BoNT/FA may offer an alternative pharmaceutical to BoNT/B1 with equal duration of action, with the benefit that it enters human cells more efficiently than BoNT/B1, thus it would be expected that significantly lower doses could be used pharmaceutically.
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